Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?

BackgroundOur previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- an...

Full description

Bibliographic Details
Main Authors: Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T. Collins, Simeng Suy, John H. Lynch, Thomas Kole, Sean P. Collins
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-07-01
Series:Frontiers in Oncology
Subjects:
stereotactic body radiation therapy
prostate cancer
PSA bounce
PSA recurrence
PSA kinetics
biochemical relapse
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00157/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00157/full

Similar Items